CD274 and non-small cell lung carcinoma: Despite the success in this phase II study, the phase III SKYSCRAPER-01 study, which evaluated tiragolumab plus atezolizumab for PD-L1-high metastatic NSCLC, did not meet its co-primary endpoint of PFS while the other co-primary endpoint of OS was immature.430 Despite this discouraging news, it is also possible that this combination of immunotherapy may have benefits in long-term efficacy indicators like OS, which has been confirmed in previous immunotherapy clinical trials.431 Before the results of OS came out, it might be too early to judge this combination therapy.